What You Should Know:
– Flatiron Health, and Lifebit Biotech Ltd (UK, London; hereafter “Lifebit”), are expanding their collaboration into Japan to transform cancer care, facilitating ground breaking research by allowing for safe and secure access to real-world data (RWD).
– Building on the success of their multi-year strategic partnership, Lifebit’s pioneering federated Trusted Research Environment (TRE) technology will enable safe and secure access to Flatiron Health’s high-quality oncology RWD.
Flatiron Health and Lifebit: Advancing Oncology Research Through Secure Data Access and Cross-Market Insights
Flatiron Health, a healthtech leader in oncology, is dedicated to expanding point-of-care solutions and leveraging data to drive smarter cancer care. Through the application of machine learning, artificial intelligence, real-world evidence, and clinical trial innovations, Flatiron Health transforms patient experiences into actionable knowledge, creating a modern and connected oncology ecosystem. An independent affiliate of the Roche Group, Flatiron Health operates globally across the U.S., the United Kingdom, Germany, and Japan, working closely with hospitals and health networks to develop region-specific strategies for utilizing real-world data (RWD) to advance cancer care.
Building on their multi-year strategic partnership, Flatiron Health has integrated Lifebit’s pioneering federated Trusted Research Environment (TRE) technology. This collaboration enables safe and secure access to Flatiron Health’s high-quality oncology RWD, allowing researchers to conduct vital research without removing data from the TRE. Lifebit’s technology ensures that data remains within Flatiron’s secure environment, where authorized researchers analyze it in situ. This approach supports the highest levels of data governance, safeguarding privacy while facilitating advanced research.
Expanding Global Reach with Secure Research-Ready Data
– Flatiron Health’s EHR-derived high-quality RWD from Japan, specifically datasets on gastric cancer, colorectal cancer, and breast cancer, are now securely accessed and utilized for oncology research via Flatiron’s TRE powered by Lifebit’s technology.
– Lifebit’s TRE technology, already implemented in major initiatives such as Genomics England, Synapxe (Singapore’s national HealthTech agency), and CanPath (Canada’s largest population health study), delivers the necessary security and data governance required for sensitive health data research.
Scientific Impact of Flatiron Health and Lifebit’s Collaboration
Flatiron Health will present findings from groundbreaking research on early-onset gastric and colorectal cancer in Japan and the U.S. at the Asian Conference of Pharmacoepidemiology (ACPE), to be held in Tokyo from October 12-14, 2024. The study utilized de-identified electronic health record (EHR)-derived datasets from Flatiron Health’s U.S. and Japan databases. These research-ready datasets, harmonized according to a standardized data model, were pooled for cross-country analysis using Lifebit’s TRE technology.
This study sets a benchmark for generating impactful evidence across markets, providing insights into regional variations in cancer progression and identifying gaps in standards of care. By facilitating cross-market comparisons, this research has the potential to improve access to care and inform future decision-making to enhance patient outcomes worldwide.
“This collaboration will enable the secure provision of sensitive oncology RWD, and significantly enhance treatment and quality of life for cancer patients,” said Eri Tajima, Head of Strategic Partnerships at Flatiron Health Japan. “By integrating Lifebit’s advanced Trusted Research Environment technology with our commitment to revolutionizing cancer research and care, we aim to unlock the full potential of cancer data. This will accelerate research into new therapies and expedite the delivery of better treatments to patients.”
